Combining two precision medicines may treat drug-resistant cancers – study

A number of the patients had previously stopped responding to chemotherapy and other targeted treatments (David Davies/PA)

Launching a dual-pronged attack on tumours using a combination of two precision medicines could treat cancer patients whose tumours have stopped responding to existing drugs, a study suggests.

The clinical trial is the first to use genetically targeted drug olaparib – already licensed for ovarian, breast and prostate cancer – together with a new medicine called capivasertib.